Lyons JM, Ito JI, Morré SA. Efficacy of an immune modulator in experimental Chlamydia trachomatis infection of the female genital tract.
Infect Dis Obstet Gynecol 2006;
2006:61265. [PMID:
17093354 PMCID:
PMC1581471 DOI:
10.1155/idog/2006/61265]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
Objective. The aim of this study was to
determine if vaginal application of the immune response
modifier imiquimod (Aldara cream, 3M Pharmaceuticals, St Paul,
Minn) would alter the course and/or outcome of female genital
tract infection with a human isolate of Chlamydia
trachomatis in a murine model. Methods. Groups
of CF-1 mice were treated with Aldara on three different
schedules: (1) ongoing beginning 5 days prior to and continuing
through day 5 of infection; (2) a single prophylactic dose 2
hours prior to infection; and (3) therapeutic from day 4
to day 14 of infection. Mice were infected vaginally
with a serovar D strain of C trachomatis, and
monitored by culture to determine the level of shedding and
duration of infection. Results. We observed a
significant reduction in both duration of infection and the level
of shedding during the acute phase in mice treated on an ongoing
basis commencing 5 days prior to infection. There was no effect
with respect to the other regimens.
Conclusion. These results demonstrate that
ongoing Aldara treatment has efficacy and may enhance local innate
immunity which reduces the duration of subsequent infection with
human isolates of C trachomatis in a murine
model of female genital tract infection.
Collapse